Occasional Male Cannabis Use Linked to Stronger Effects

UCLA researchers report that occasional male cannabis users experience the strongest and most unpleasant highs, even when their blood THC levels equal those of occasional female users. The finding challenges the notion that infrequent use is inherently gentle for men.

The study enrolled 44 healthy adults, evenly divided into men and women, and grouped them as occasional or frequent users. Each person inhaled a 0% THC control, a moderate 4% THC cigarette, and a high‑dose 10% THC cigarette in random order, with blood draws and self‑ratings recorded.

Occasional‑use men rated their high roughly 30 points above occasional women and frequent men on a 100‑point scale at the moderate dose, and they also reported greater sedation, impairment, anxiety and overall distress. Heart rate rose only in this group after adjusting for blood THC, confirming a distinct physiological response.

Frequent users, both sexes, consistently chose to spend money on additional puffs, with about 20% buying more after the control, 40% after the moderate dose and over half after the strong dose. Occasional users showed no increase in desire, peaking at the same rate as the control.

Researchers suggest lower tolerance from infrequent exposure explains the intense reactions in occasional men, while occasional women tended to be slightly older and had longer usage histories, which likely contributed to higher tolerance. Sex alone did not predict the magnitude of effects, indicating that use frequency interacts with biology.

The trial’s modest sample size and reliance on self‑rated mood limit generalizability, and the authors note that follow‑up analyses—not pre‑registered comparisons—drive the most striking findings. The cannabis doses were lower than typical commercial products, so the findings are unlikely to reflect real‑world use.

Funding came from the National Institute on Drug Abuse, the National Center for Complementary and Integrative Health, UCLA’s Clinical and Translational Science Institute and the Semel Charitable Foundation, with additional fellowships from several NIH agencies. Disclosures show author Ziva D. Cooper received drug donations from Canopy Growth Corp and True Terpenes, and other authors report no relevant financial conflicts.

A larger, longer‑term study is needed to confirm whether occasional use poses unique risks for men before product labels or health guidance can be updated. Regulatory implications await further validation.